High-definition spatial transcriptomics for in situ tissue profiling
- PMID: 31501547
- PMCID: PMC6765407
- DOI: 10.1038/s41592-019-0548-y
High-definition spatial transcriptomics for in situ tissue profiling
Abstract
Spatial and molecular characteristics determine tissue function, yet high-resolution methods to capture both concurrently are lacking. Here, we developed high-definition spatial transcriptomics, which captures RNA from histological tissue sections on a dense, spatially barcoded bead array. Each experiment recovers several hundred thousand transcript-coupled spatial barcodes at 2-μm resolution, as demonstrated in mouse brain and primary breast cancer. This opens the way to high-resolution spatial analysis of cells and tissues.
Conflict of interest statement
Competing interests
F.S., J.F., J.L. and P.L.S. are authors on patents PCT/EP2012/056823 (WO2012/140224), PCT/EP2013/071645 (WO2014/060483) and PCT/EP2016/057355 applied for by Spatial Transcriptomics AB (10x Genomics) covering the described technology. M.R. is employed by Illumina Inc. A.R. is a founder and equity holder of Celsius Therapeutics and an SAB member of Syros Pharmaceuticals and Thermo Fisher Scientific.
Figures


References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases